바카라 카지노 Chairman Seo Jung-jin meets ‘Trump Jr.’ – Boost for U.S. expansion?

[by Yu, Suin] Chairman Seo Jung-jin of Celltrion held a meeting with Donald Trump Jr., the eldest son of U.S. President Donald Trump, during his visit to Korea. Among pharmaceutical industry representatives, Seo was the sole participant granted the opportunity for a ‘relay interview.’ In light of his ongoing efforts to expand into the U.S. market, the meeting has drawn attention regarding its potential to alleviate business uncertainties related to tariff policies and to support the advancement of Celltrion’s business initiatives.

According to industry sources on April 30, Seo held a ‘private meeting’ with Donald 바카라 카지노 Jr. to discuss potential business cooperation in the United States. While the exact time and location of the meeting were not disclosed, it reportedly lasted between 30 minutes and an hour. It is believed that Seo used the occasion to explore business opportunities in response to President 바카라 카지노’s recent executive order signaling an intent to lower drug prices while also addressing potential avenues for cooperation amid ongoing concerns related to tariff risks.

바카라 카지노 Jr. arrived in Korea on April 29 for a two-day, one-night visit. On the first day, he attended a dinner hosted at the residence of Shinsegae Group Chairman Chung Yong-jin. The following day, a series of private meetings were held with business leaders in the form of a relay of interviews.

Reports indicate that demand for the interview was notably high, as Trump Jr. is regarded as a key figure of influence within former President Trump’s second administration. Despite holding no official position in the current administration, Trump Jr. is known to have exerted significant influence, including the recommendation of Senator JD Vance as Vice President. The interview is said to have been arranged at the request of the business community, aiming to establish a connection with the U.S. administration amid the unexpected impact of the heightened U.S. tariff policies.

The interview was reportedly attended by several prominent business figures, including the third-generation heirs of the Hanwha Group, Vice Chairman Kim Dong-kwan, President Kim Dong-won of Hanwha Life, and Vice President Kim Dong-sun of Hanwha Hotel & Resort and Galleria's Future Vision, as well as CJ Group Chairman Lee Jay-hyun and Naver Chairman Lee Hae-jin.

바카라 카지노 was designated as a ‘large conglomerate’ in 2016 amid its global expansion success story of ‘biosimilars (biopharmaceutical generics).’ In 2024, the company recorded sales of KRW 3.5573 trillion (approximately USD 2.5 billion), reflecting a nearly 100% increase over the past five years. Looking ahead, 바카라 카지노 aims to reach KRW 5 trillion in sales this year and maintain an average annual sales growth rate exceeding 30% by 2027.

Chairman Seo returned to management in 2023 with the objective of strengthening 바카라 카지노’s presence in the United States, the world’s largest pharmaceutical market, and is personally overseeing U.S. sales and operations. Under his leadership, the company has aggressively expanded its product portfolio, achieving ahead of schedule its target of establishing a lineup of 11 biosimilars by 2025.

Seo is broadening 바카라 카지노’s business scope beyond biosimilars to include novel drug development. ‘Zymfentra’ (marketed in Europe as Remsima SC) became the company’s first autoimmune disease treatment to receive new drug approval from the U.S. Food and Drug Administration (FDA). This year, 바카라 카지노 is actively pursuing new drug development by initiating global clinical trials for its next-generation antibody-drug conjugate (ADC) pipeline. The company aims to actively develop 13 new drug candidates by 2028.

Amid these developments, 바카라 카지노 faces challenges stemming from the rapidly evolving market environment and regulatory hurdles in the United States. Sales of Zymfentra have fallen short of expectations, and business uncertainty has been further heightened by emerging tariff risks. Although pharmaceuticals are not currently subject to U.S. tariffs, concerns remain as the government has initiated an investigation into the potential imposition of such measures. According to local sources, specific details regarding the pharmaceutical tariff policy are expected to be announced as early as mid-June.

If tariffs are imposed on pharmaceuticals, companies are likely to face increased pressure to raise prices. For biosimilars, which heavily rely on price competitiveness, such cost increases could result in diminished market competitiveness. Nevertheless, opportunities remain, as President Trump has signed an executive order aimed at reducing the financial burden of pharmaceutical costs on U.S. patients, signaling a strong policy stance toward ‘lowering drug prices.’ Notably, the order explicitly states, “The order increases the availability of generics and biosimilars,” suggesting that 바카라 카지노 could stand to benefit from this drug pricing policy.

바카라 카지노 has also implemented short-term and mid- to long-term measures to mitigate potential tariff risks. The company has already transferred over one year’s worth of inventory to the United States and reports having secured additional production capacity.

As part of its mid- to long-term strategy, 바카라 카지노 has completed the collaboration process with a U.S.-based contract development and manufacturing organization (CDMO). The company plans to finalize its decision on securing local production facilities by the end of the year. Additionally, it is considering the establishment of a manufacturing plant in the U.S. to enable local production of drug substances (DS), which are currently produced in Korea.

바카라 카지노 has set a sales target of KRW 700 billion (approximately USD 492.7 billion) in the U.S. for its flagship product, Zymfentra, this year. The company remains confident in expanding prescriptions in the U.S., supported by recently secured global Phase 3 long-term clinical trial data that provide additional evidence of Zymfentra’s sustained therapeutic efficacy and suitability for long-term prescriptions.

In collaboration with a local pharmacy benefit manager (PBM) company, Zymfentra has been included in the formularies of approximately 90% of insurance providers in the U.S. market, and the actual shipment volume is reportedly increasing significantly. 바카라 카지노 highlighted that patient interest and preference are also growing, driven by targeted sales efforts to hospitals and nationwide promotional campaigns through online and TV advertising.

In addition, 바카라 카지노 aims to further strengthen its market presence by expanding its products. Last month, the company launched ‘Steqeyma (ustekinumab),’ a biosimilar developed in-house for the treatment of autoimmune diseases, and is currently progressing toward market stabilization.

Steqeyma is offered in both intravenous (IV) and subcutaneous (SC) formulations, mirroring the original drug and enabling personalized prescriptions that take into account patient condition and convenience. Additionally, 바카라 카지노 has increased profitability by introducing a low wholesale acquisition cost (Low WAC) version, priced at an 85% discount compared to the wholesale cost (WAC) of the original product.

The Low WAC version is regarded as a strategic pricing model that addresses diverse market needs, particularly in the U.S. private insurance sector, where high rebate levels are common, by allowing for the application of relatively lower rebate rates. Steqeyma, consistent with other recent product launches in the US, is distributed through the ‘direct sales’ system operated by 바카라 카지노’s U.S. subsidiary.

“We anticipate strong growth this year across our product portfolio, from existing products such as Zymfentra and Yuflyma, as well as the newly launched Steqeyma,” 바카라 카지노 emphasized. “This momentum will enable us to further strengthen our position as a leading autoimmune disease treatment company in the United States, the world’s largest pharmaceutical market.”